---
title: 'AbbVie, Third Rock, Scholar Rock, Kyowa Kirin'
type: 'episode'
url: 'https://doc.social/episodes/abbvie-third-rock-scholar-rock-kyowa-kirin'
show: 'Life Science Today'
show_url: 'https://doc.social/podcasts/life-science-today'
published: '2022-06-22'
audio: 'unavailable — the host retired the file'
---

# AbbVie, Third Rock, Scholar Rock, Kyowa Kirin

Crohn’s approval, new VC round, direct offerings, and potential asset sales. Find out more athttps://LifeScienceTodayPodcast.comStory ReferencesAbbVieThird RockScholar RockKyowa Kirin About the ShowLife Science Today is your source for stor…

## Summary

Crohn’s approval, new VC round, direct offerings, and potential asset sales.

**Find out more at
**[https://LifeScienceTodayPodcast.com
](https://lifesciencetodaypodcast.com/)
**Story References
**[AbbVie](https://www.biospace.com/article/releases/skyrizi-risankizumab-rzaa-receives-fda-approval-as-the-first-and-only-specific-interleukin-23-il-23-to-treat-moderately-to-severely-active-crohn-s-disease-in-adults/?s=74)
[Third Rock
](https://www.biospace.com/article/in-tough-biotech-market-third-rock-raises-new-1-1-billion-fund/?s=80)[Scholar Rock
](https://www.biospace.com/article/releases/scholar-rock-announces-205-million-registered-direct-offering/)[Kyowa Kirin**
**](https://seekingalpha.com/news/3849135-kyowa-kirin-mulling-sale-of-certain-pharma-assets-for-1b-bloomberg-news)
**About the Show
**Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.